Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.

@article{Treanor2006DoserelatedSA,
  title={Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.},
  author={John Jay Treanor and Gilbert M. Schiff and Robert B. Couch and Thomas R. Cate and Rebecca C. Brady and Christine Mhorag Hay and Mark Wolff and Dewei She and Manon M. J. Cox},
  journal={The Journal of infectious diseases},
  year={2006},
  volume={193 9},
  pages={1223-8}
}
BACKGROUND Influenza-virus hemagglutinin (HA) protein expressed in insect cells by recombinant baculovirus is a candidate influenza vaccine. METHODS In a randomized, double-blind trial conducted in 399 adults > or = 65 years of age, the efficacy of trivalent inactivated influenza vaccine (TIV) licensed for intramuscular injection was compared with that of trivalent baculovirus-expressed HA vaccine administered at doses of 15 microg, 45 microg, or 135 microg of each HA. RESULTS Compared with… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 20 references

in healthy adults

  • RB Belshe, FK Newman, J Cannon
  • 2002

Similar Papers

Loading similar papers…